Alnylam Pharmaceuticals
Manufacturing · Massachusetts, United States · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
675 W Kendall Street Henri A. Termeer Sq...Phone Number
(617) 551-8200Website
www.alnylam.comRevenue
$4.3 BillionStock Symbol
ALNYIndustry
ZI Rank: 2
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
12
1
2
2
2
2
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemRead more
Alnylam Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alnylam Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Alnylam Pharmaceuticals launches new products
Check out if Alnylam Pharmaceuticals is spiking on competitors!
Click to see if Alnylam Pharmaceuticals had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Alnylam Pharmaceuticals
Website visits: Recent activity has been detected on your website
Check if Alnylam Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Alnylam Pharmaceuticals has new funding data
Earning: See what the market has to say on Alnylam Pharmaceuticals recently announced quarterly report
Alnylam Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Alnylam Pharmaceuticals as Masked Content
Find 2 more new buyers
Compare Similar Companies to Alnylam Pharmaceuticals
Compare insights from companies similar to Alnylam Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Alnylam Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Alnylam Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals financials insights
Gather financial insights about Alnylam Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2004
Stock Offering
$30.2M
2011
Corporate Investment
$10M
2020
Private Equity
$2B
Other Financing Round
$150M
Alnylam Pharmaceuticals Tech Stack
A closer look at the technologies used by Alnylam Pharmaceuticals
Most Recent Scoops
Project
Alnylam Pharmaceuticals has reported Phase I proof of mechanism for ALN-6400, demonstrating that a single dose produced a deep antifibrinolytic effect sustained for three months significantly more durable than oral tranexamic acid, whose effect lasts only hours leading to the selection of two dose levels for Phase II studies based on mechanistically superior and more durable antifibrinolytic activity.
Proof of Concept (POC), Pharmaceuticals
Project
Alnylam Pharmaceuticals has completed its Phase I double-blind, placebo-controlled study of ALN-6400, which tested four ascending single-dose levels in healthy adult volunteers and incorporated an innovative oral tranexamic acid benchmark run-in and washout period, with full data expected to be shared in the second half of this year.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Alnylam Pharmaceuticals is conducting HM BEACON, a multinational Phase II study of ALN-6400 in adult and adolescent patients with all types of von Willebrand disease and heavy menstrual bleeding, with goals of evaluating safety and tolerability, determining the Phase III dose and regimen, and establishing proof of concept through reduction in menstrual bleeding, with a Phase III trial planned where the primary endpoint is anticipated to be annualized bleeding rate.
Project
Alnylam Pharmaceuticals has reported that genetic, proteomic, and preclinical data indicate that low plasminogen levels are not associated with increased arterial or venous thrombosis risk, with natural history data from 107 patients with plasminogen deficiency showing no history of venous thrombosis and preclinical thrombosis models confirming no alteration in thrombin generation.
Project
Medical Research, Clinical Operations
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Alnylam Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatme... Read More
